Cencora amends and restates revolving credit facility, extending maturity to October 2028

Cencora, Inc.

Senior unsecured multi-currency Revolving Credit Facility amended to extend maturity from 2025 to October 6, 2028.
Interest margins range from 80.5 to 122.5 bps over Term SOFR/EURIBOR/CDOR based on Cencora's public debt ratings.
Facility fees range from 7 to 15 bps per annum on total commitments, also determined by debt ratings.
Letters of credit sublimit of US $100 million; proceeds used for general corporate purposes.
Customary affirmative and negative covenants, including limitations on subsidiary indebtedness and leverage ratio.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cencora, Inc. amended Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-10-06).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent
Effective: 2023-10-06

Exact text from the filing

On October 6, 2023, Cencora, Inc. (the “Company”) and its subsidiaries BP Pharmaceuticals Laboratories Unlimited Company, Centaur Services Limited and Innomar Strategies Inc. entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) to amend and restate the Amended and Restated Credit Agreement, dated as of October 27, 2022, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

View on SEC.gov

295 material agreements filed in the last 30 days. Browse all material agreements →

Cencora, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-108288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.